Key Points
- Director Scott Garrett bought 177,936 shares of HCW Biologics at an average price of $1.41, bringing his direct holdings to 203,441 shares and boosting his ownership by 697.65%.
- HCW Biologics last reported quarterly EPS of $0.37, beating the consensus estimate of a $0.44 loss, while revenue came in at $6.54 million as expected.
- The stock remains small and volatile, with a market cap of $13.06 million; analysts currently view it as a Hold overall, and institutional ownership is relatively limited at 2.96%.
HCW Biologics Inc. (NASDAQ:HCWB - Get Free Report) CFO Rebecca Byam acquired 14,235 shares of the stock in a transaction on Friday, May 22nd. The stock was bought at an average cost of $1.41 per share, with a total value of $20,071.35. Following the completion of the transaction, the chief financial officer owned 57,245 shares in the company, valued at $80,715.45. This trade represents a 33.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
HCW Biologics Price Performance
HCW Biologics stock opened at $1.94 on Thursday. The stock has a market cap of $13.06 million, a price-to-earnings ratio of -0.21 and a beta of 1.13. HCW Biologics Inc. has a 1 year low of $0.25 and a 1 year high of $8.75. The firm has a 50-day moving average of $0.72 and a two-hundred day moving average of $1.15.
HCW Biologics (NASDAQ:HCWB - Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.81. The company had revenue of $6.54 million during the quarter, compared to analysts' expectations of $6.54 million. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%.
Institutional Investors Weigh In On HCW Biologics
A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC purchased a new stake in HCW Biologics Inc. (NASDAQ:HCWB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 300,180 shares of the company's stock, valued at approximately $291,000. Armistice Capital LLC owned approximately 9.15% of HCW Biologics as of its most recent filing with the SEC. Institutional investors and hedge funds own 2.96% of the company's stock.
Analyst Ratings Changes
HCWB has been the subject of several recent research reports. Wall Street Zen upgraded shares of HCW Biologics to a "hold" rating in a report on Saturday, May 23rd. Weiss Ratings restated a "sell (e+)" rating on shares of HCW Biologics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $35.00.
View Our Latest Analysis on HCWB
About HCW Biologics
(
Get Free Report)
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
